학술논문
Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
Document Type
Journal
Author
Iwata, Hiroji; Baselga, Jose; Campone, Mario; Arteaga, Carlos L.; Cortes, Javier; Jonat, Walter; De Laurentiis, Michelino; Ciruelos, Eva; Janni, Wolfgang; Bachelot, Thomas; Lonning, Per Eystein; Ma, Cynthia; O'Regan, Ruth; Di Tomaso, Emmanuelle; Bharani-Dharan, Bharani; Duval, Vincent; Lau, Helen; Germa, Caroline; Urban, Pabrick; Di Leo, Angelo
Source
Subject
Language
English
ISSN
15277755